Monday, 09 December 2019

Hyphens Pharma inks MoU with A*STAR for Derma research

22 March 2019 | News

Hyphens intends to develop innovative and differentiated dermatological products to address unmet market needs.

Hyphens is currently licensing sugar-based surfactant micro-emulsions technology from A*STAR’s Institute of Chemical and Engineering Sciences (ICES).

By leveraging A*STAR’s research and development capabilities, it is envisioned that this MoU will enable Hyphens to develop innovative and differentiated dermatological products to address unmet market needs.

Hyphens is a Singapore-headquartered ASEAN specialty pharma company. Operating in six countries across the region, Hyphens has a strong medical, regulatory and commercial capability. Dermatology is a key therapeutic focus field where Hyphens markets products under the brands “Ceradan” and “TDF”.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is APAC region emerging as a leader in assistive technologies?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls